Y-mAbs Therapeutics, Inc.: key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2024)

$87.7M

Net Income/Loss (FY2024)

-$29.7M

Total Assets (FY2024)

$119.9M

Total Equity (FY2024)

$92.0M

Cash Flows from Operating Activities (FY2024)

-$15.7M

Source: Y-mAbs Therapeutics, Inc. 10-K filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.